Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
45 stopped studies mapped to Malignant Muscle Neoplasm and descendants · 91% state a reason
Over the 45 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients… | Phase 3 | terminated | Nov 13, 2009 | National Cancer Institute (NCI) | The study was targeted to accrue 130 patients, but closed early for futility. | Efficacy / futility |
| NCT04890093 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults… | Phase 1 / Phase 2 | suspended | May 18, 2021 | National Cancer Institute (NCI) | Pending updated agreements in order to enroll additional participants. | Enrollment / accrual |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or… | Phase 2 | terminated | Aug 28, 2020 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | Phase 2 / Phase 3 | terminated | Mar 8, 2022 | PTC Therapeutics | Business decision | Sponsor / business decision |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid…(STIR) | Phase 2 | terminated | Apr 1, 2014 | Monica Thakar | 15 patients enrolled out of planned 20, terminated due to slow enrollment at end of study | Enrollment / accrual |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With… | Phase 1 | terminated | Dec 22, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | Phase 2 | withdrawn | Mar 10, 2021 | Children's National Research Institute | Low enrollment. | Enrollment / accrual |
| NCT04996004 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and…(TTI-621-03) | Phase 2 | terminated | Aug 9, 2021 | Pfizer | Pfizer decided to terminate the study for administrative reasons. The termination was neither due… | Safety / toxicity |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | Phase 1 | terminated | Sep 13, 2018 | Fred Hutchinson Cancer Center | The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was… | Enrollment / accrual |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT02940041 | Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal…(CERTUM) | — | terminated | Oct 20, 2016 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Not enough patients included | Other (stated, no rule matched) |
| NCT05116683 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma(ATX-101) | Phase 2 | terminated | Nov 11, 2021 | Benjamin Izar | Study terminated by PI | Other (stated, no rule matched) |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Phase 1 / Phase 2 | terminated | Mar 8, 2018 | Bayer | no anticipated benefit over available standard therapies | Other (stated, no rule matched) |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | Phase 2 | withdrawn | Dec 30, 2021 | David Liebner, MD | PI decision | Other (stated, no rule matched) |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric… | Phase 1 | terminated | Aug 31, 2015 | AeRang Kim | low accrual | Enrollment / accrual |
| NCT01958580 | Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With… | N/A | terminated | Oct 9, 2013 | Albert Einstein College of Medicine | Study terminated due to low accrual. PI left the institution | Investigator |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in…(PIVOT IO 020) | Phase 1 / Phase 2 | terminated | Jan 29, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT03959033 | Patient Reported Outcome Measures (PROMs) With Trabectedin | — | terminated | May 22, 2019 | University of Leeds | Insufficient accrual | Enrollment / accrual |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Nov 10, 2015 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT03074318 | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is… | Phase 1 / Phase 2 | terminated | Mar 8, 2017 | Fred Hutchinson Cancer Center | Terminated due to PI leaving institution | Other (stated, no rule matched) |
| NCT03041701 | Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination… | Phase 1 / Phase 2 | terminated | Feb 3, 2017 | National Cancer Institute (NCI) | The pharmaceutical company discontinued availability of the drug and we were forced to close the… | Enrollment / accrual |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Phase 2 | withdrawn | Nov 11, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With… | Phase 2 | withdrawn | May 28, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma,… | Phase 1 / Phase 2 | terminated | Oct 21, 2015 | Dana-Farber Cancer Institute | The study closed primarily due to weak accrual, as well as study design limitations. | Enrollment / accrual |
| NCT03509207 | Vorinostat (SAHA) in Uterine Sarcoma | Phase 2 | terminated | Apr 26, 2018 | Medical University of Graz | The early termination was NOT due to safety reasons, terminated because of the very slow… | Safety / toxicity |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or… | Phase 3 | terminated | Feb 15, 2012 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | Phase 1 | terminated | Jan 29, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory… | Phase 2 | withdrawn | Feb 23, 2016 | Washington University School of Medicine | Could not recruit any participants | Enrollment / accrual |
| NCT03773510 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin(TRADITIONS) | Phase 3 | withdrawn | Dec 12, 2018 | Italian Sarcoma Group | Not approved by the coordinating Ethical Committee | Other (stated, no rule matched) |
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric… | Phase 1 | withdrawn | Sep 23, 2015 | Theodore Laetsch | Lack of enrollment | Enrollment / accrual |
| NCT03437070 | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent… | Phase 1 | withdrawn | Feb 19, 2018 | University of Miami | Sponsor Decision | Sponsor / business decision |
| NCT00414076 | Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma | Phase 2 | terminated | Dec 21, 2006 | M.D. Anderson Cancer Center | Low accrual | Enrollment / accrual |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | Phase 2 | withdrawn | Dec 13, 2013 | Children's Oncology Group | IND no longer available. | Other (stated, no rule matched) |
| NCT03111069 | Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and… | Phase 1 | withdrawn | Apr 12, 2017 | M.D. Anderson Cancer Center | PI withdrew study | Other (stated, no rule matched) |
| NCT01418001 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the… | Phase 1 / Phase 2 | terminated | Aug 16, 2011 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT00944580 | A Vaccine Study for High Risk Cancers | Phase 1 | withdrawn | Jul 23, 2009 | Penn State University | unexpectedly low screening results leading to poor accrual | Enrollment / accrual |
| NCT00003292 | S9624 Ifosfamide in Treating Patients With Meningeal Tumors | Phase 2 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
| NCT01697514 | A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma | Phase 1 | withdrawn | Oct 2, 2012 | Eli Lilly and Company | Trial stopped early for poor accrual. | Enrollment / accrual |
| NCT01112800 | Markers of Anthracycline-Related Cardiac Muscle Injury | — | withdrawn | Apr 28, 2010 | St. Jude Children's Research Hospital | not stated | Not stated |
| NCT00087191 | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or… | N/A | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00162695 | Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood | Phase 3 | terminated | Sep 13, 2005 | Gustave Roussy, Cancer Campus, Grand Paris | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials